



UNIVERSITY OF LEEDS

This is a repository copy of *Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/119692/>

Version: Supplemental Material

Article:

Lardas, M, Liew, M, van den Bergh, R et al. (21 more authors) (2017) Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. *European Urology*, 72 (6). pp. 869-885. ISSN 0302-2838

<https://doi.org/10.1016/j.eururo.2017.06.035>

(c) 2017, European Association of Urology. Published by Elsevier B.V. This manuscript version is made available under the CC BY-NC-ND 4.0 license
<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results	Reported p-values or Hazard Ratios with confidence intervals
					Age adjusted cross-sectional UCLA-PCI quality of life outcomes (95% CI) Higher values refer to better function	Multivariate UCLA-PCI cross-sectional outcomes
Bacon 2001 UCLA-PCI	Radical prostatectomy	421	NR	Up to 60 months	Sexual function 26 (23–29) Sexual bother 43 (39–47) Urinary function 76 (74–78) Urinary bother 82 (80–85) Bowel function 86 (85–88) Bowel bother 86 (84–89)	Reference
	Radiotherapy	221			Sexual function 34 (30–38) Sexual bother 51 (46–57) Urinary function 89 (86–92) Urinary bother 83 (80–87) Bowel function 81 (78–83) Bowel bother 78 (75–82)	Sexual function <0.05 <i>favouring EBRT</i> Sexual bother <0.05 <i>favouring EBRT</i> Urinary function <0.05 <i>favouring EBRT</i> Urinary bother NSS Bowel function NSS <i>favouring RP</i> Bowel bother NSS <i>favouring RP</i>
	Brachytherapy	69			Sexual function 36 (30–42) Sexual bother 54 (45–64) Urinary function 87 (82–92) Urinary bother 75 (68–81) Bowel function 80 (76–84) Bowel bother 72 (66–78)	Sexual function <0.05 <i>favouring BT</i> Sexual bother <0.05 <i>favouring BT</i> Urinary function <0.05 <i>favouring RP</i> Urinary bother <0.05 <i>favouring RP</i> Bowel function <0.05 <i>favouring RP</i> Bowel bother <0.05 <i>favouring RP</i>

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
			Unadjusted mean (95% CI) EPIC score Higher values refer to better function		Unadjusted mean (95% CI) EPIC score at 12 months Higher values refer to better function	Unadjusted mean (95% CI) EPIC score at 36 months Higher values refer to better function	P value for differences in EPIC scores at 12 months	P value for differences in EPIC scores at 36 months
Barocas 2017 EPIC	Radical prostatectomy	1523	Urinary incontinence: 86.7 (85.5-87.8) Urinary irritative: 83.2 (82.3-84.1) Sexual function: 65.2 (63.5-66.9) Bowel function: 94.0 (93.3-94.6) Hormone function: 89.8 (89.1-90.5)	40 months (38-45)	Urinary incontinence: 70.7 (69.2-72.1) Urinary irritative: 89.6 (88.9-90.3) Sexual function: 37.1 (35.4-38.7) Bowel function: 94.8 (94.2-95.4) Hormone function: 88.5 (0.4)	Urinary incontinence: 71.8 (70.4-73.2) Urinary irritative: 90.3 (89.6-91.0) Sexual function: 40.7 (38.9-42.6) Bowel function: 95.0 (94.4-95.6) Hormone function: 89.5 (0.4)	Urinary incontinence: <0.001 favouring EBRT Urinary irritative: 0.012 favouring RP but the difference between groups did not exceed the minimally important difference for clinical significance Sexual function: <0.001 favouring EBRT Bowel function: <0.001 favouring RP but the difference between groups did not exceed the minimally important difference for clinical significance Hormone function: 0.005 favouring RP	Urinary incontinence: <0.001 favouring EBRT Urinary irritative: <0.001 favouring RP but the difference between groups did not exceed the minimally important difference for clinical significance Sexual function: <0.001 favouring EBRT Bowel function: <0.001 favouring RP but the difference between groups did not exceed the minimally important difference for clinical significance Hormone function: 0.77
	Radiotherapy	598	Urinary incontinence: 88.2 (86.7-89.6) Urinary irritative: 82.3 (80.9-83.7) Sexual function: 52.3 (49.6-55.0) Bowel function: 93.4 (92.5-94.3) Hormone function: 86.7 (85.3-88.0)		Urinary incontinence: 86.4 (84.8-88.1) Urinary irritative: 84.8 (83.5-86.0) Sexual function: 38.4 (35.6-41.2) Bowel function: 88.6 (87.4-89.9) Hormone function: 82.7 (0.8)	Urinary incontinence: 85.3 (83.4-87.1) Urinary irritative: 85.9 (84.6-87.3) Sexual function: 38.9 (35.8-42.0) Bowel function: 90.3 (89.1-91.6) Hormone function: 87.1 (0.7)		

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results	Reported p-values or Hazard Ratios with confidence intervals	
					QLQ-C30 quality of life scores (mean) at 12 months Higher values refer to better function	p values within-group test for change in score	P values for differences between groups (Wilcoxon rank-sum-test)
Borchers 2004 EORTC-QLQ-C30	NS Radical prostatectomy	38	Physical 95 Role 81 Emotional 61 Cognitive 86 Social 75 Sexual 75 Overall 68	12	Physical 93 Role 90 Emotional 81 Cognitive 82 Social 80 Sexual 56 Overall 75	Physical 0,16 Role 0,26 Emotional <0.001 Cognitive 0.13 Social 0.49 Sexual 0.001 Overall 0.15	<u>Physical</u> RP + NS vs RP 0.77 RP + NS vs BT 0.94 RP vs BT 0.84 <u>Role</u> RP + NS vs RP 0.10 RP + NS vs BT 0.50 RP vs BT 0.28 <u>Emotional</u> RP + NS vs RP 0.32 RP + NS vs BT 0.03 <i>favouring NSRP</i> RP vs BT 0.21 <u>Cognitive</u> RP + NS vs RP 0.87 RP + NS vs BT 0.79 RP vs BT 0.73 <u>Social</u> RP + NS vs RP 0.03 RP + NS vs BT 0.35 RP vs BT 0.21 <u>Sexual</u> RP + NS vs RP 0.45 RP + NS vs BT 0.14 RP vs BT 0.015 <i>favouring BT</i> <u>Overall</u> RP + NS vs RP 1.0 RP + NS vs BT 0.47 RP vs BT 0.55
	Non-NS Radical prostatectomy	42	Physical 91 Role 93 Emotional 65 Cognitive 91 Social 83 Sexual 66 Overall 65		Physical 91 Role 87 Emotional 78 Cognitive 86 Social 74 Sexual 42 Overall 70	Physical 0.92 Role 0.26 Emotional 0.02 Cognitive 0.14 Social 0.16 Sexual <0.001 Overall 0.30	
	Brachytherapy	52	Physical 91 Role 90 Emotional 67 Cognitive 87 Social 77 Sexual 61 Overall 65		Physical 90 Role 90 Emotional 76 Cognitive 86 Social 77 Sexual 53 Overall 66	Physical 0.76 Role 1,0 Emotional 0.08 Cognitive 0.63 Social 1,0 Sexual 0.17 Overall 0.78	

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
					EPIC mean score difference from baseline (SD) to 12 months	EPIC mean score difference from baseline (SD) to 24 months	EPIC mean score difference from baseline at 24 months 95% CI	P values from multivariate models of domain score change from baseline to 2-years
Evans 2015 EPIC	Brachytherapy	262	Bowel: 96 / 100 ± 8.3 Sexual: 67 / 75 ± 29 Hormone: 93 / 100 ± 11 Urinary incontinence: 94 / 100 ± 12 Urinary obstruction: 90 / 94 ± 13	24	Bowel: -7,01 (15,10) Hormone: -2,91 (11,89) Sexual: -14,88 (22,03) Urinary incontinence: -4,41 (16,60) Urinary obstruction: -8,68 (16,95)	Bowel: -7,14 (16,09) Hormone: -1,72 (12,27) Sexual: -18,24 (24,43) Urinary incontinence: -6,33 (18,45) Urinary obstruction: -6,11 (17,51)	Bowel: -9.21--5.06 Hormone: -3.31--0.137 Sexual: -21.6--14.9 Urinary incontinence: -8.76--3.9 Urinary obstruction: -8.4--3.82	<u>Bowel</u> Brachytherapy vs. IMRT 0.48 SBRT vs. IMRT 0.00014 <i>favouring SBRT</i> SBRT vs. Brachy 0.001 in <i>favouring SBRT</i>
	IMRT	160	Bowel: 94 / 100 ± 11 Sexual: 61 / 67 ± 29 Hormone: 92 / 95 ± 12 Urinary incontinence: 93 / 100 ± 13 Urinary obstruction: 86 / 88 ± 14		Bowel: -6,77 (16,48) Hormone: -2,20 (12,24) Sexual: -13,43 (22,83) Urinary incontinence: -3,74 (15,55) Urinary obstruction: 1,03 (15,74)	Bowel: -7,59 (16,61) Hormone: -2,14 (12,72) Sexual: -13,80 (26,60) Urinary incontinence: -4,72 (15,95) Urinary obstruction: 1,84 (14,03)	Bowel: -10.4--4.81 Hormone: -4.27--0.0165 Sexual: -18.4--9.17 Urinary incontinence: -7.46--1.98 Urinary obstruction: -0.509-4.2	<u>Hormone</u> Brachytherapy vs. IMRT 0.78 SBRT vs. IMRT 0.84 SBRT vs. Brachy 0.63 <u>Sexual</u> Brachytherapy vs. IMRT 0.18
	SBRT	381	Bowel: 95 / 100 ± 9.1 Sexual: 55 / 58 ± 31 Hormone: 94 / 100 ± 10 Urinary incontinence: 92 / 100 ± 13 Urinary obstruction: 87 / 88 ± 12		Bowel: -3,39 (11,28) Hormone: -0,84 (9,54) Sexual: -7,11 (20,42) Urinary incontinence: -3,99 (12,57) Urinary obstruction: -2,95 (14,03)	Bowel: -1,27 (9,13) Hormone: -1,12 (9,39) Sexual: -8,95 (21,02) Urinary incontinence: -3,38 (14,00) Urinary obstruction: -0,17 (12,09)	Bowel: -2.41--0.14 Hormone: -2.28-0.0516 Sexual: -11.6--6.35 Urinary incontinence: -5.12--1.65 Urinary obstruction: -1.67-1.32	SBRT vs. IMRT 0.57 SBRT vs. Brachy 0.46 <u>Urinary incontinence</u> Brachytherapy vs. IMRT 0,21 SBRT vs. IMRT 0.74 SBRT vs. Brachy 0.11 <u>Urinary obstruction</u> Brachytherapy vs. IMRT <0.0001 <i>favouring IMRT</i> SBRT vs. IMRT 0.55 SBRT vs. Brachy 0.00051 <i>favouring SBRT</i>

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals														
					Adjusted Mean Differences in EPIC scores between RP and AS patients at 1 year Mean (95% CI)	Adjusted Mean Differences in EPIC scores between RP and AS patients at 2 years Mean (95% CI)	P value for differences in EPIC scores at 1 year	P value for differences in EPIC scores at 2 years													
Jeldres 2015 EPIC	Active Surveillance	77	urinary function: 93 ± 10 urinary bother: 84 ± 14 sexual function: 51 ± 26 sexual bother: 70 ± 29 bowel function: 94 ± 8 bowel bother: 96 ± 7 Hormone function: 91 ± 10 Hormone bother: 95 ± 8	27 ± 17	urinary function: -14(-18, -11) urinary bother: -5 (-9, -2) sexual function: -27 (-32, -22) sexual bother: -29 (-36, -21) bowel function: -3 (-5, -1) bowel bother: -2 (-4, 0) Hormone function: -3 (-6, 1) Hormone bother: -1 (-4, 2)	urinary function: -15 (-19, -11) urinary bother: -2 (-6, 2) sexual function: -17 (-23, -10) sexual bother: -18 (-29, -7) bowel function: -1 (-3, 1) bowel bother: -2 (-4, 1) Hormone function: -1 (-5, 4) Hormone bother: -2 (-6, 1)	urinary function: <.0001 urinary bother: .04 sexual function: <.0001 sexual bother: <.0001 bowel function: .06 bowel bother: .74 Hormone function: .96 Hormone bother: 1.00	urinary function: <.0001 urinary bother: 1.00 sexual function: .0005 sexual bother: .03 bowel function: 1.00 bowel bother: 1.00 Hormone function: 1.00 Hormone bother: 1.00													
	Radical Prostatectomy	228	urinary function: 95 ± 10 urinary bother: 85 ± 16 sexual function: 62 ± 22 sexual bother: 79 ± 29 bowel function: 93 ± 8 bowel bother: 94 ± 11 Hormone function: 91 ± 11 Hormone bother: 95 ± 9	36 ± 17										Adjusted Mean Differences in EPIC scores between RP and AS patients at 3 years Mean (95% CI)	Adjusted Mean Absolute Changes EPIC scores from Baseline at 1 year Mean (95% CI)	P value for differences in EPIC scores at 3 years	P value for absolute changes in EPIC scores at 1 year		Active Surveillance	77	
					Adjusted Mean Differences in EPIC scores between RP and AS patients at 3 years Mean (95% CI)	Adjusted Mean Absolute Changes EPIC scores from Baseline at 1 year Mean (95% CI)	P value for differences in EPIC scores at 3 years	P value for absolute changes in EPIC scores at 1 year													
	Active Surveillance	77			urinary function: -9 (-15, -3) urinary bother: -1 (-6, 5) sexual function: -14 (-21, -7) sexual bother: -19 (-31, -7) bowel function: -1 (-5, 4) bowel bother: -1 (-5, 3) Hormone function: -1 (-6, 4) Hormone bother: -2 (-5, 1)	urinary function: -1 (-4, 3) urinary bother: 2 (-3, 6) sexual function: -2 (-7, 4) sexual bother: -3 (-11, 5) bowel function: 2 (-1, 4) bowel bother: 1 (-2, 3) Hormone function: -2 (-5, 2) Hormone bother: -1 (-4, 1)	urinary function: 0.046 <i>favouring AS</i> urinary bother: 1	urinary function: 1 urinary bother: 1 sexual function: 1 sexual bother: 1 bowel function: 1 bowel bother: 1 Hormone function: 1													

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
Jeldres cont.							sexual function: 0.01 <i>favouring AS</i> sexual bother: 0.049 <i>favouring AS</i>	Hormone bother: 1
	Radical Prostatectomy	228				urinary function: -15 (-19, -11) urinary bother: -2 (-6, 1) sexual function: -31 (-36, -26) sexual bother: -34 (-41, -27) bowel function: -1 (-3, 1) bowel bother: 0 (-3, 2) Hormone function: -4 (-7, -1) Hormone bother: -2 (-4, 1)	bowel function: 1 bowel bother: 1 Hormone function: 1 Hormone bother: 1	urinary function:<0.0001 urinary bother: 1 sexual function: <0.0001 sexual bother: <0.0001 bowel function: 1 bowel bother: 1 Hormone function: 0.03 Hormone bother: 1
					Adjusted Mean Absolute Changes in EPIC scores from baseline at 2 years Mean (95% CI)	Adjusted Mean Absolute Changes in EPIC scores from baseline at 3 years Mean (95% CI)	P value for absolute changes in EPIC scores at 2 years	P value for absolute changes in EPIC scores at 3 years
Jeldres cont.	Active Surveillance	77			urinary function:1 (-3, 5) urinary bother: 1 (-4, 5) sexual function: -4 (-11, 2) sexual bother: -6 (-17, 6) bowel function: 0 (-2, 3) bowel bother: 2 (-1, 4) Hormone function: -2 (-6, 2) Hormone bother: 0 (-3, 3)	urinary function: -5 (-11, 1) urinary bother: -2 (-7, 4) sexual function: -6 (-14, 2) sexual bother: -5 (-17, 7) bowel function: -1 (-6, 4) bowel bother: -1 (-4, 3) Hormone function: -3 (-8, 2) Hormone bother: 0 (-3, 2)	urinary function:1 urinary bother: 1 sexual function: 1 sexual bother: 1 bowel function: 1 bowel bother: 1 Hormone function: 1 Hormone bother: 1	urinary function:0.64 urinary bother: 1 sexual function: 0.89 sexual bother: 1 bowel function: 1 bowel bother: 1 Hormone function: 1 Hormone bother: 1
	Radical Prostatectomy	228			urinary function: -14 (-18, -11) urinary bother: 0 (-4, 3) sexual function: -24 (-29, -19) sexual bother: -26 (-33, -19) bowel function: 0 (-2, 2) bowel bother: 1 (-1, 4) Hormone function: -2 (-5, 1) Hormone bother: -1 (-4, 1)	urinary function: -15 (-19, -11) urinary bother: -1 (-5, 3) sexual function: -23 (-28, -17) sexual bother: -24 (-32, -17) bowel function: -1 (-4, 1) bowel bother: 0 (-3, 3) Hormone function: -4 (-6, -1) Hormone bother: -1 (-4, 1)	urinary function:<0.0001 urinary bother: 1 sexual function: <0.0001 sexual bother: <0.0001 bowel function: 1 bowel bother: 1 Hormone function: 1 Hormone bother: 1	urinary function:<0.0001 urinary bother: 1 sexual function: <0.0001 sexual bother: <0.0001 bowel function: 1 bowel bother: 1 Hormone function: 0.04 Hormone bother: 1

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
					UCLA-PCI scores (mean) at 12 months Higher values refer to better function		P values	
Kobuke 2009 UCLA-PCI	Radical prostatectomy	37	Urinary function: 86.44 Urinary bother: 87.16 Bowel function: 91.40 Bowel bother: 90.70 Sexual function: 37.07 Sexual bother: 81.75	12	Urinary function: 65.34 Urinary bother: 87.09 Bowel function: 92.03 Bowel bother: N/A Sexual function: 9.97 Sexual bother: 62.09		Urinary function: NSS Urinary bother: NSS Bowel function: NSS Bowel bother: NSS Sexual function: < 0.05 favouring BT Sexual bother: NSS	
	Brachytherapy	36	Urinary function: 89.77 Urinary bother: 87.5 Bowel function: 86.33 Bowel bother: 93.75 Sexual function: 35.77 Sexual bother: 75		Urinary function: 82.06 Urinary bother: 85 Bowel function: 86.21 Bowel bother: N/A Sexual function: 38.13 Sexual bother: 75.89			
					UCLA-PCI scores (Average percent baseline scores) at 12 months outcomes were compared with Kruskal-Wallis rank test using PBS (calculated by dividing follow-up function or bother score by baseline function or bother score) Higher values refer to better function	UCLA-PCI scores (Average percent baseline scores) at 18 months outcomes were compared with Kruskal-Wallis rank test using PBS (calculated by dividing follow-up function or bother score by baseline function or bother score) Higher values refer to better function	P value at 12 months*	P value at 18 months*
	Open Radical prostatectomy	135	urinary function:89 (18) urinary bother: 92 (15) sexual function: 74 (18) sexual bother: 86 (20) bowel function:87 (14) bowel bother: 92 (15)	36	urinary function:79 urinary bother: 84 sexual function: 43 sexual bother: 40 bowel function:102 bowel bother: 99	urinary function: 82 urinary bother: 85 sexual function: 48 sexual bother: 46 bowel function: 103 bowel bother: 100		

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
Malcolm 2010 UCLA-PCI							*authors report p values taking into consideration the cryotherapy arm which we have not included in our review	*authors report p values taking into consideration the cryotherapy arm which we have not included in our review
	Robotic Radical prostatectomy	447	urinary function:92 (13) urinary bother: 93 (14) sexual function: 73 (17) sexual bother: 84 (20) bowel function:88 (14) bowel bother: 94 (13)		urinary function:74 urinary bother: 81 sexual function: 40 sexual bother: 47 bowel function:103 bowel bother: 100	urinary function: 74 urinary bother: 81 sexual function: 42 sexual bother: 51 bowel function: 103 bowel bother: 100		
	Brachytherapy	122	urinary function:90 (16) urinary bother: 89 (17) sexual function: 64 (19) sexual bother: 80 (21) bowel function:84 (16) bowel bother: 88 (18)		urinary function:94 urinary bother: 88 sexual function: 71 sexual bother: 63 bowel function:103 bowel bother: 99	urinary function: 90 urinary bother: 87 sexual function: 68 sexual bother: 67 bowel function: 106 bowel bother: 96		
					UCLA-PCI scores (Average percent baseline scores) at 24 months Higher values refer to better function	UCLA-PCI scores (Average percent baseline scores) at 30 months Higher values refer to better function	P value at 24 months*	P value at 30 months*
Malcolm cont.	Open Radical prostatectomy	135			urinary function: 84 urinary bother: 87 sexual function: 46 sexual bother: 52 bowel function: 104 bowel bother: 102	urinary function: 82 urinary bother: 88 sexual function: 50 sexual bother: 54 bowel function: 102 bowel bother: 96	*authors report p values taking into consideration the cryotherapy arm which we have not included in our review	*authors report p values taking into consideration the cryotherapy arm which we have not included in our review
	Robotic Radical prostatectomy	447			urinary function: 76 urinary bother: 83 sexual function: 45 sexual bother: 48 bowel function: 101 bowel bother: 97	urinary function: 75 urinary bother: 85 sexual function: 41 sexual bother: 52 bowel function: 102 bowel bother: 99		
	Brachytherapy	122			urinary function: 90 urinary bother: 94	urinary function: 90 urinary bother: 91		

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
					sexual function: 74 sexual bother: 78 bowel function: 110 bowel bother: 101	sexual function: 67 sexual bother: 67 bowel function: 109 bowel bother: 100		
					UCLA-PCI scores (Average percent baseline scores) at 36 months Higher values refer to better function		P value at 36 months*	
Malcolm cont.	Open Radical prostatectomy	135			urinary function: 83 urinary bother: 88 sexual function: 48 sexual bother: 58 bowel function: 101 bowel bother: 99		* authors report p values taking into consideration the cryotherapy arm which we have not included in our review	
	Robotic Radical prostatectomy	447			urinary function: 78 urinary bother: 86 sexual function: 46 sexual bother: 45 bowel function: 102 bowel bother: 94			
	Brachytherapy	122			urinary function: 88 urinary bother: 90 sexual function: 73 sexual bother: 85 bowel function: 107 bowel bother: 99			

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results	Reported p-values or Hazard Ratios with confidence intervals
					UCLA-PCI scores (mean) at 12 months Higher values refer to better function	P value
Namiki 2006 UCLA-PCI	Radical prostatectomy	67	urinary function: 92.9 ± 18.1 urinary bother: 92.3 ± 27.1 bowel function: 87.9 ± 15.1 bowel bother: 93.1 ± 20.9 sexual function: 37.9 ± 24.7 sexual bother: 71.8 ± 27.4	12	urinary function: 75.7 ± 20.4 urinary bother: 85.2 ± 20.5 bowel function: 86.1 ± 13.7 bowel bother: 87.5 ± 15.9 sexual function: 10.2 ± 15.2 sexual bother: 55.4 ± 33.2	urinary function: <0.001 <i>favouring BT</i> urinary bother: NSS bowel function: NSS bowel bother: NSS sexual function: <0.001 <i>favouring BT</i> sexual bother: 0.032 <i>favouring BT</i>
	Brachytherapy	70	urinary function: 88.8 ± 14.6 urinary bother: 81.2 ± 25.6 bowel function: 87.7 ± 13.9 bowel bother: 88.3 ± 17.8 sexual function: 34.4 ± 23.3 sexual bother: 72.2 ± 21.4		urinary function: 92.4 ± 19.2 urinary bother: 88.9 ± 24.2 bowel function: 88.8 ± 10.6 bowel bother: 86.1 ± 21.5 sexual function: 32.0 ± 12.6 sexual bother: 69.1 ± 34.8	
					Mean changes in EPIC scores from baseline to 3 years mean (SD) Negative values refer to worse function	P values
	Radical prostatectomy	123	Urinary incontinence: 94.5 (15.1) Urinary obstruction: 93.4 (11.1) Bowel: 97.9 (3.7) Sexual: 59.0 (23.5) Hormonal: 94.0 (9.1)		<u>Non-nerve sparing</u> Urinary incontinence: -26.3 (28.8) Urinary obstruction: -1.8 (14.4) Bowel: 1.3 (3.1) Sexual: -23.4 (25.7) Hormonal: -1.7 (12.8)	

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
Pardo 2010 EPIC					<u>Nerve sparing</u> Urinary incontinence: -21.4 (25.2) Urinary obstruction: 7.0 (13.1) Bowel: 1.7 (4.5) Sexual: -25.3 (28.2) Hormonal: 2.4 (15.5)		Urinary incontinence: <0.001 favouring EBRT and BT over RP Urinary obstruction: 0.002 favouring NSRP only over EBRT and BT Bowel: 0.006 favouring non-NSRP and BT only over EBRT Sexual: <0.001 favouring EBRT and BT over RP Hormonal: 0.034 favouring NSRP only over EBRT	
	External-beam radiotherapy	127	Urinary incontinence: 96.3 (9.9) Urinary obstruction: 95.5 (9.5) Bowel: 97.8 (4.5) Sexual: 54.1 (23.2) Hormonal: 95.7 (8.4)	36	Urinary incontinence: -6.7 (17.8) Urinary obstruction: -5.6 (15.9) Bowel: -3.2 (11.1) Sexual: -10.6 (22.4) Hormonal: -5.0 (14.1)			
	Brachytherapy	185	Urinary incontinence: 96.1 (11.1) Urinary obstruction: 94.4 (11.1) Bowel: 96.5 (7.2) Sexual: 55.9 (23.3) Hormonal: 95.5 (8.0)		Urinary incontinence: -7.4 (20.7) Urinary obstruction: -5.9 (21.0) Bowel: 0.3 (11.8) Sexual: -9.9 (23.5) Hormonal: -2.0 (10.7)			
					EPIC mean function and bother scores at median 16 months Higher values refer to better function	Mean difference on EPIC scores from baseline to 16 months (bold numbers indicate significant differences between treatment groups)	P value for EPIC mean scores at 16 months	P value for mean difference on EPIC scores between same group
	Brachytherapy	52	Urinary function: 97 (100;100;100) Urinary incontinence: 94 (100;100;100) Urinary obstructive/irritative: 100 (100;100;100) Urinary bother: 90 (86;93;100)		Urinary function: 91 (89;100;100) Urinary incontinence: 90 (83;100;100) Urinary obstructive/irritative: 93 (100;100;100) Urinary bother: 82 (68;89;100) Urinary incontinence bother: 86 (94;100;100)	Urinary function: 6 (0;0;11) Urinary incontinence: 5 (0;0;10) Urinary obstructive/irritative: 7 (0;0;0) Urinary bother: 8 (0;4;21) Urinary incontinence bother: 11 (0;0;0)		Urinary function: p < 0.01 Urinary incontinence: NSS Urinary obstructive/irritative: p < 0.01 Urinary bother: p < 0.01

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results	Reported p-values or Hazard Ratios with confidence intervals		
Pinkawa 2009 EPIC			Urinary incontinence bother: 97 (100;100;100) Urinary obstructive/irritative bother: 90 (85;95;100) Bowel function: 94 (92;96;100) Bowel bother: 94 (93;100;100) Sexual function: 46 (32;50;62) Sexual bother: 72 (50;75;100) Hormonal function: 91 (88;100;100) Hormonal bother: 92 (92;100;100)	16	Urinary obstructive/irritative bother: 82 (66;87;100) Bowel function: 93 (92;96;100) Bowel bother: 93 (93;100;100) Sexual function: 42 (25;41;59) Sexual bother: 61 (31;63;88) Hormonal function: 92 (88;100;100) Hormonal bother: 92 (88;100;100)	Urinary obstructive/irritative bother: 7 (-4;5;15) Bowel function: 1 (-3;0;4) Bowel bother: 2 (-3;0;4) Sexual function: 7 (-3;6;18) Sexual bother: 12 (-6;6;38) Hormonal function: -1 (-6;0;5) Hormonal bother: 1 (0;0;4)	Urinary function: NSS Urinary incontinence: NSS Urinary obstructive/irritative: $p = 0.03$ favouring EBRT Urinary bother: NSS Urinary incontinence bother: NSS Urinary obstructive/irritative bother: NSS Bowel function: NSS Bowel bother: NSS Sexual function: $p < 0.01$ Sexual bother: $p < 0.05$ Hormonal function: NSS Hormonal bother: NSS	Urinary incontinence bother: $p < 0.01$ Urinary obstructive/irritative bother: $p < 0.01$ Bowel function: NSS Bowel bother: NSS Sexual function: $p < 0.01$ Sexual bother: $p < 0.05$ Hormonal function: NSS Hormonal bother: NSS
	External beam radiotherapy	52	Urinary function: 94 (90;100;100) Urinary incontinence: 91 (90;100;100) Urinary obstructive/irritative: 98 (100;100;100) Urinary bother: 83 (68;89;96) Urinary incontinence bother: 94 (100;100;100) Urinary obstructive/irritative bother: 82 (70;87;95) Bowel function: 93 (88;96;100) Bowel bother: 95 (93;100;100) Sexual function: 43 (29;44;56) Sexual bother: 67 (44;81;100) Hormonal function: 87 (75;94;100) Hormonal bother: 89 (83;96;100)		Urinary function: 94 (94;100;100) Urinary incontinence: 90 (90;100;100) Urinary obstructive/irritative: 99 (100;100;100) Urinary bother: 88 (83;93;96) Urinary incontinence bother: 92 (100;100;100) Urinary obstructive/irritative bother: 87 (80;90;100) Bowel function: 89 (82;92;96) Bowel bother: 87 (79;96;100) Sexual function: 37 (12;32;59) Sexual bother: 60 (31;69;94) Hormonal function: 91 (88;100;100) Hormonal bother: 91 (88;100;100)	Urinary function: 0 (0;0;4) Urinary incontinence: 1 (0;0;10) Urinary obstructive/irritative: -1 (0;0;0) Urinary bother: -5 (-11;0;4) Urinary incontinence bother: 1 (0;0;0) Urinary obstructive/irritative bother: -5 (-15; -4;0) Bowel function: 4 (0;0;8) Bowel bother: 7 (0;0;11) Sexual function: 6 (-6;3;22) Sexual bother: 5 (0;7;19) Hormonal function: -3 (-12;0;0) Hormonal bother: -1 (-5;0;0)	Urinary function: NSS Bowel function: NSS Bowel bother: NSS Sexual function: NSS Sexual bother: NSS Hormonal function: NSS Hormonal bother: NSS	Urinary function: NSS Urinary incontinence: NSS Urinary obstructive/irritative: NSS Urinary bother: $p < 0.05$ Urinary incontinence bother: NSS Urinary obstructive/irritative bother: NSS Bowel function: $p < 0.05$ Bowel bother: $p < 0.01$ Sexual function: $p < 0.01$ Sexual bother: $p < 0.01$ Hormonal function: NSS Hormonal bother: NSS

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals
					Unadjusted proportion of 3294 men who experienced a clinically meaningful decline in UCLA-PCI score of at least half standard deviation from baseline to 2 years by primary treatment modality n/n (%)	Unadjusted proportion of 3294 men who experienced a clinically meaningful decline in UCLA-PCI score of at least half standard deviation from baseline to 5 years by primary treatment modality n/n (%)	
Punnen 2014 UCLA-PCI	NS Radical prostatectomy	1139	Sexual function: 65 (26) Sexual bother: 71 (34) Urinary function: 93 (12) Urinary bother: 89 (19) Bowel function: 90 (12) Bowel bother: 93 (16)	74	Sexual function: 590/919 (64) Sexual bother: 550/905 (61) Urinary function: 499/921 (54) Urinary bother: 279/926 (30) Bowel function: 179/934 (19) Bowel bother: 160/930 (17)	Sexual function: 367/594 (62) Sexual bother: 300/578 (52) Urinary function: 349/592 (59) Urinary bother: 180/598 (30) Bowel function: 112/601 (19) Bowel bother: 106/598 (18)	
	Non NS Radical prostatectomy	860	Sexual function: 54 (28) Sexual bother: 61 (37) Urinary function: 93 (13) Urinary bother: 85 (24) Bowel function: 88 (14) Bowel bother: 90 (20)		Sexual function: 461/681 (68) Sexual bother: 359/671 (54) Urinary function: 370/680 (54) Urinary bother: 214/683 (31) Bowel function: 162/696 (23) Bowel bother: 139/689 (20)	Sexual function: 282/421 (67) Sexual bother: 207/411 (51) Urinary function: 247/419 (59) Urinary bother: 116/416 (28) Bowel function: 93/426 (22) Bowel bother: 90/426 (21)	
	Brachytherapy	684	Sexual function: 43 (30) Sexual bother: 54 (39) Urinary function: 92 (13) Urinary bother: 83 (24) Bowel function: 88 (14) Bowel bother: 88 (21)		Sexual function: 204/513 (40) Sexual bother: 212/503 (42) Urinary function: 194/536 (36) Urinary bother: 191/533 (36) Bowel function: 146/539 (27) Bowel bother: 153/538 (28)	Sexual function: 136/305 (45) Sexual bother: 123/297 (41) Urinary function: 137/312 (44) Urinary bother: 99/310 (32) Bowel function: 87/314 (28) Bowel bother: 76/317 (24)	
	EBRT	386	Sexual function: 35 (28) Sexual bother: 53 (40) Urinary function: 91 (14) Urinary bother: 81 (27) Bowel function: 87 (13) Bowel bother: 86 (23)		Sexual function: 106/277 (38) Sexual bother: 104/270 (39) Urinary function: 70/295 (24) Urinary bother: 69/298 (23) Bowel function: 91/296 (31) Bowel bother: 100/295 (34)	Sexual function: 64/158 (41) Sexual bother: 56/152 (37) Urinary function: 61/166 (37) Urinary bother: 43/163 (26) Bowel function: 46/164 (28) Bowel bother: 46/162 (28)	

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
					Unadjusted proportion of 3294 men who experienced a clinically meaningful decline in UCLA-PCI score of at least half standard deviation from baseline to 10 yr by primary treatment modality n/n (%)	Adjusted likelihood of a clinically significant decline in UCLA-PCI score of at least half standard deviation from baseline to 2 yr by primary treatment modality among 3297 men in the study cohort OR (95% CI)		P value for 2 years
Punnen cont.	NS Radical prostatectomy	1139			Sexual function: 96/137 (70) Sexual bother: 74/133 (56) Urinary function: 100/144 (69) Urinary bother: 49/142 (35) Bowel function: 30/142 (21) Bowel bother: 29/141 (21)	Sexual function: 1 Sexual bother: 1 Urinary function: 1 Urinary bother: 1 Bowel function: 1 Bowel bother: 1		<u>Sexual function</u> NSRP 1 Non-NSRP <0.01 BT <0.01 EBRT <0.01 <u>Sexual bother</u> NSRP 1 Non-NSRP 0.7 BT 0.06 EBRT 0.07
	Non NS Radical prostatectomy	860			Sexual function: 83/116 (72) Sexual bother: 53/115 (46) Urinary function: 68/115 (59) Urinary bother: 49/112 (44) Bowel function: 35/115 (30) Bowel bother: 32/116 (28)	Sexual function: 1.6 (1.2–2.1) Sexual bother: 1.0 (0.7–1.2) Urinary function: 1.0 (0.8–1.2) Urinary bother: 1.1 (0.8–1.4) Bowel function: 1.1 (0.8–1.4) Bowel bother: 1.0 (0.8–1.4)		<u>Urinary function</u> NSRP 1 Non-NSRP 0.7 BT <0.01 EBRT <0.01 <u>Urinary bother</u> NSRP 1 Non-NSRP 0.5 BT 0.08 EBRT 0.3
	Brachytherapy	684			Sexual function: 53/80 (66) Sexual bother: 30/76 (39) Urinary function: 44/82 (54) Urinary bother: 33/85 (39) Bowel function: 28/84 (33) Bowel bother: 29/84 (35)	Sexual function: 0.5 (0.4–0.7) Sexual bother: 0.7 (0.5–1.0) Urinary function: 0.4 (0.3–0.6) Urinary bother: 1.3 (1.0–1.8) Bowel function: 1.3 (1.0–1.8) Bowel bother: 1.6 (1.1–2.2)		<u>Bowel function</u> NSRP 1 Non-NSRP 0.7 BT 0.08 EBRT <0.01 <u>Bowel bother</u> NSRP 1 Non-NSRP 0.7 BT <0.01 EBRT <0.01
	EBRT	386			Sexual function: 18/34 (53) Sexual bother: 10/33 (30) Urinary function: 19/36 (53) Urinary bother: 17/36 (47) Bowel function: 15/35 (43) Bowel bother: 8/34 (24)	Sexual function: 0.5 (0.3–0.8) Sexual bother: 0.7 (0.4–1.0) Urinary function: 0.3 (0.2–0.4) Urinary bother: 0.8 (0.5–1.2) Bowel function: 1.8 (1.2–2.7) Bowel bother: 2.3 (1.5–3.5)		

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
					Adjusted likelihood of a clinically significant decline in UCLA-PCI score of at least half standard deviation from baseline to 5 yr by primary treatment modality among 3297 men in the study cohort OR (95% CI)	Adjusted likelihood of a clinically significant decline in UCLA-PCI score of at least half standard deviation from baseline to 10 yr by primary treatment modality among 3297 men in the study cohort OR (95% CI)	P value for 5 years	P value for 10 years
Punnen cont.	NS Radical prostatectomy	1139			Sexual function: 1 Sexual bother: 1 Urinary function: 1 Urinary bother: 1 Bowel function: 1 Bowel bother: 1	Sexual function: 1 Sexual bother: 1 Urinary function: 1 Urinary bother: 1 Bowel function: 1 Bowel bother: 1	<u>Sexual function:</u> NSRP 1 Non-NSRP <0.01 BT 0.2 EBRT 0.3 WW/AS 0.03	<u>Sexual function:</u> NSRP 1 Non-NSRP <0.01 BT 0.8 EBRT 0.7
	Non NS Radical prostatectomy	860			Sexual function: 2.0 (1.4–2.8) Sexual bother: 1.4 (1.0–1.9) Urinary function: 1.0 (0.7–1.3) Urinary bother: 0.8 (0.6–1.1) Bowel function: 1.1 (0.8–1.5) Bowel bother: 1.1 (0.7–1.5)	Sexual function: 3.6 (1.5–8.6) Sexual bother: 1.1 (0.6–2.1) Urinary function: 0.7 (0.4–1.2) Urinary bother: 1.8 (1.0–3.4) Bowel function: 1.6 (0.8–3.1) Bowel bother: 1.1 (0.6–2.2)	<u>Sexual bother:</u> NSRP 1 Non-NSRP 0.03 BT 0.4 EBRT 0.7 WW/AS 0.3	<u>Sexual bother:</u> NSRP 1 Non-NSRP 0.8 BT 0.7 EBRT 0.3
	Brachytherapy	684			Sexual function: 0.8 (0.5–1.2) Sexual bother: 1.2 (0.8–1.7) Urinary function: 0.5 (0.3–0.7) Urinary bother: 1.0 (0.7–1.5) Bowel function: 1.6 (1.0–2.3) Bowel bother: 1.1 (0.7–1.6)	Sexual function: 0.9 (0.3–2.6) Sexual bother: 1.2 (0.5–2.9) Urinary function: 0.5 (0.3–1.1) Urinary bother: 1.2 (0.6–1.7) Bowel function: 3.3 (1.4–7.4) Bowel bother: 2.3 (1.0–5.2)	<u>Urinary function:</u> NSRP 1 Non-NSRP 0.8 BT <0.01 EBRT <0.01 WW/AS <0.01	<u>Urinary bother:</u> NSRP 1 Non-NSRP 0.06 BT 0.6 EBRT 0.6
	EBRT	386			Sexual function: 0.8 (0.4–1.3) Sexual bother: 1.1 (0.6–1.9) Urinary function: 0.3 (0.2–0.5) Urinary bother: 0.8 (0.5–1.3) Bowel function: 1.8 (1.0–3.0) Bowel bother: 1.5 (0.9–2.6)	Sexual function: 0.7 (0.2–3.4) Sexual bother: 0.5 (0.2–1.8) Urinary function: 0.2 (0.1–0.6) Urinary bother: 1.3 (0.5–3.7) Bowel function: 4.0 (1.3–11.7) Bowel bother: 1.1 (0.3–3.5)	<u>Bowel function:</u> NSRP 1 Non-NSRP 0.7 BT 0.03 EBRT 0.03 WW/AS 0.5	<u>Bowel bother:</u> NSRP 1 Non-NSRP 0.7 BT 0.05 EBRT 0.9

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
					Percentage (%) of 5-year PCOS survey responders reporting bother on urinary, bowel, and sexual domain items	Percentage (%) of 15-year PCOS survey responders reporting bother on urinary, bowel, and sexual domain items	OR (95% CI) for responders reporting bother at 5 years OR for the prostatectomy group as compared with the radiotherapy group	OR (95% CI) for responders reporting bother at 15 years OR for the prostatectomy group as compared with the radiotherapy group
Resnick 2013, Potosky 2004, Potosky 2000 PCOS questionnaire	Radical prostatectomy	1164	NR	180	Urinary incontinence No control or frequent urinary leakage: 13.4 Bothered by dripping or leaking urine: 12.9 Sexual function Erection insufficient for intercourse: 75.7 Bothered by sexual dysfunction: 46.7 Bowel function Bowel urgency: 16.3 Bothered by frequent bowel movements, pain, or urgency: 4.4	Urinary incontinence No control or frequent urinary leakage: 18.3 Bothered by dripping or leaking urine: 17.1 Sexual function Erection insufficient for intercourse: 87 Bothered by sexual dysfunction: 43.5 Bowel function Bowel urgency: 21.9 Bothered by frequent bowel movements, pain, or urgency: 5.2	Urinary incontinence 5.10 (2.29–11.36) 7.66 (2.97–19.89) Sexual function 1.96 (1.05–3.63) 1.48 (0.92–2.39) Bowel Function 0.47 (0.26–0.84) 0.93 (0.27–3.22)	Urinary incontinence 2.34 (0.88–6.23) 0.87 (0.41–1.80) Sexual function 0.38 (0.12–1.22) 1.33 (0.58–3.03) Bowel Function 0.98 (0.45–2.14) 0.29 (0.11–0.78)
	EBRT	491			Urinary incontinence No control or frequent urinary leakage: 4.4 Bothered by dripping or leaking urine: 2.9 Sexual function Erection insufficient for intercourse: 71.9 Bothered by sexual dysfunction: 39.7 Bowel function Bowel urgency: 31.3 Bothered by frequent bowel movements, pain, or urgency: 5.8	Urinary incontinence No control or frequent urinary leakage: 9.4 Bothered by dripping or leaking urine: 18.4 Sexual function Erection insufficient for intercourse: 93.9 Bothered by sexual dysfunction: 37.7 Bowel function Bowel urgency: 35.8 Bothered by frequent bowel movements, pain, or urgency: 16.0		

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
					EPIC scores (mean ± SD) at 12 months Higher values refer to better function	EPIC scores (mean ± SD) at 24 months Higher values refer to better function	95% CI at 12 months	95% CI at 24 months
Sanda 2008 EPIC	Radical prostatectomy	603	<u>non-NSRP</u> Urinary Incontinence: 94 ± 12 Urinary Irritative: 87 ± 14 Bowel: 95 ± 9 Sexual: 70 ± 27 Hormonal: 91 ± 12	30	<u>non-NSRP</u> Urinary Incontinence: 73 ± 28 Urinary Irritative: 89 ± 17 Bowel: 92 ± 16 Sexual: 25 ± 29 Hormonal: 84 ± 22	<u>non-NSRP</u> Urinary Incontinence: 73 ± 30 Urinary Irritative: 91 ± 12 Bowel: 94 ± 11 Sexual: 25 ± 28 Hormonal: 84 ± 22	<u>non-NSRP</u> Urinary Incontinence: 63-83 Urinary Irritative: 84-95 Bowel: 86-97 Sexual: 15-35 Hormonal: 77-92	<u>non-NSRP</u> Urinary Incontinence: 62-84 Urinary Irritative: 86-96 Bowel: 90-98 Sexual: 14-36 Hormonal: 76-92
			<u>NSRP</u> Urinary Incontinence: 93 ± 12 Urinary Irritative: 87 ± 14 Bowel: 96 ± 7 Sexual: 79 ± 22 Hormonal: 91 ± 11		<u>NSRP</u> Urinary Incontinence: 79 ± 23 Urinary Irritative: 92 ± 11 Bowel: 95 ± 8 Sexual: 38 ± 29 Hormonal: 91 ± 12	<u>NSRP</u> Urinary Incontinence: 81 ± 22 Urinary Irritative: 92 ± 10 Bowel: 96 ± 8 Sexual: 45 ± 31 Hormonal: 92 ± 14	<u>NSRP</u> Urinary Incontinence: 77-81 Urinary Irritative: 91-93 Bowel: 95-96 Sexual: 35-40 Hormonal: 90-92	<u>NSRP</u> Urinary Incontinence: 78-83 Urinary Irritative: 91-93 Bowel: 95-97 Sexual: 41-48 Hormonal: 90-93
	EBRT	292	<u>EBRT alone</u> Urinary Incontinence: 92 ± 14 Urinary Irritative: 86 ± 13 Bowel: 94 ± 10 Sexual: 60 ± 28 Hormonal: 90 ± 12		<u>EBRT alone</u> Urinary Incontinence: 90 ± 17 Urinary Irritative: 88 ± 14 Bowel: 87 ± 17 Sexual: 49 ± 31 Hormonal: 90 ± 12	<u>EBRT alone</u> Urinary Incontinence: 88 ± 16 Urinary Irritative: 89 ± 13 Bowel: 88 ± 17 Sexual: 48 ± 30 Hormonal: 90 ± 12	<u>EBRT alone</u> Urinary Incontinence: 87-92 Urinary Irritative: 86-90 Bowel: 85-90 Sexual: 45-54 Hormonal: 88-92	<u>EBRT alone</u> Urinary Incontinence: 85-91 Urinary Irritative: 87-91 Bowel: 84-91 Sexual: 43-54 Hormonal: 88-92
			<u>EBRT and NHT</u> Urinary Incontinence: 91 ± 13 Urinary Irritative: 87 ± 13 Bowel: 95 ± 7 Sexual: 56 ± 30 Hormonal: 93 ± 10		<u>EBRT and NHT</u> Urinary Incontinence: 87 ± 15 Urinary Irritative: 87 ± 13 Bowel: 88 ± 16 Sexual: 29 ± 26 Hormonal: 82 ± 16	<u>EBRT and NHT</u> Urinary Incontinence: 89 ± 15 Urinary Irritative: 86 ± 15 Bowel: 86 ± 19 Sexual: 25 ± 25 Hormonal: 85 ± 17	<u>EBRT and NHT</u> Urinary Incontinence: 84-91 Urinary Irritative: 84-91 Bowel: 85-92 Sexual: 23-35 Hormonal: 78-85	<u>EBRT and NHT</u> Urinary Incontinence: 84-93 Urinary Irritative: 82-91 Bowel: 81-92 Sexual: 18-33 Hormonal: 80-90

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results		Reported p-values or Hazard Ratios with confidence intervals	
	Brachytherapy	306	<u>BT alone</u> Urinary Incontinence: 93 ± 11 Urinary Irritative: 89 ± 12 Bowel: 96 ± 8 Sexual: 66 ± 29 Hormonal: 93 ± 11 <u>BT and EBRT, NHT or both (NOT INCLUDED IN THE REVIEW)</u> Urinary Incontinence: 94 ± 13 Urinary Irritative: 90 ± 11 Bowel: 92 ± 13 Sexual: 61 ± 33 Hormonal: 94 ± 9		<u>BT alone</u> Urinary Incontinence: 89 ± 16 Urinary Irritative: 81 ± 18 Bowel: 89 ± 16 Sexual: 52 ± 30 Hormonal: 90 ± 13 <u>BT and EBRT, NHT or both (NOT INCLUDED IN THE REVIEW)</u> Urinary Incontinence: 94 ± 11 Urinary Irritative: 80 ± 18 Bowel: 88 ± 21 Sexual: 45 ± 31 Hormonal: 88 ± 14	<u>BT alone</u> Urinary Incontinence: 87 ± 18 Urinary Irritative: 84 ± 15 Bowel: 88 ± 16 Sexual: 48 ± 30 Hormonal: 91 ± 12 <u>BT and EBRT, NHT or both (NOT INCLUDED IN THE REVIEW)</u> Urinary Incontinence: 84 ± 27 Urinary Irritative: 80 ± 23 Bowel: 87 ± 18 Sexual: 54 ± 31 Hormonal: 93 ± 13	<u>BT alone</u> Urinary Incontinence: 87-91 Urinary Irritative: 78-83 Bowel: 87-91 Sexual: 48-56 Hormonal: 88-92 <u>BT and EBRT, NHT or both (NOT INCLUDED IN THE REVIEW)</u> Urinary Incontinence: 90-99 Urinary Irritative: 73-87 Bowel: 80-95 Sexual: 34-57 Hormonal: 83-93	<u>BT alone</u> Urinary Incontinence: 84-90 Urinary Irritative: 81-86 Bowel: 86-91 Sexual: 43-53 Hormonal: 89-93 <u>BT and EBRT, NHT or both (NOT INCLUDED IN THE REVIEW)</u> Urinary Incontinence: 70-98 Urinary Irritative: 67-92 Bowel: 78-97 Sexual: 38-70 Hormonal: 86-101
					Change in UCLA-PCI scores between pre-treatment and 12 months		P values for change in EPIC scores from baseline to 12 months	
Schapira 2001 UCLA-PCI	Radical prostatectomy	42	Urinary function: 90 Urinary bother: 82 Sexual function: 58 Sexual bother: 64 Bowel function: 88 Bowel bother: 91	12	Urinary function: -27.8 Urinary bother: -15.3 Sexual function: -38.4 Sexual bother: -34.6 Bowel function: -0.5 Bowel bother: -4.7		Urinary function: 0.004 <i>favouring EBRT</i> Urinary bother: NSS Sexual function: 0.001 <i>favouring EBRT</i> Sexual bother: NSS Bowel function: NSS Bowel bother: NSS	
	Radiotherapy	51	Urinary function: 89 Urinary bother: 80 Sexual function: 39 Sexual bother: 55 Bowel function: 89 Bowel bother: 86		Urinary function: 0.4 Urinary bother: 1.3 Sexual function: -13.9 Sexual bother: 5.1 Bowel function: -9.6 Bowel bother: -9.4			

Supplementary table 2: Summary of results for prospective studies

Author, year, PROM tool used	Interventions	N at baseline	Baseline QoL mean scores (SD)	Follow up (months)	Reported Results	Reported p-values or Hazard Ratios with confidence intervals
			Baseline EPIC score mean (99% confidence interval)		EPIC scores at 1 year mean (99% confidence interval)	
Symon 2006 EPIC	Radical prostatectomy	24	Urinary irritative: 87.7 (79.6–95.8) Urinary incontinence: 92.9 (85.6–100) Bowel: 92.6 (86.2–99.1) Sexual: 62.1 (47.7–77.5) Hormonal: 97.3 (81.9–92.7)	12	Urinary irritative: 91 (86.3–95.7) Urinary incontinence: 84.9 (74.2–95.5) Bowel: 95.6 (91.5–99.7) Sexual: 31.5 (16.8–46.1) Hormonal: 93.2 (88.1–98.3)	NR
	EBRT	26	Urinary irritative: 86.2 (80.4–92) Urinary incontinence: 94.4 (88.9–99.9) Bowel: 95.7 (93.6–97.8) Sexual: 51.6 (38.6–64.7) Hormonal: 89 (81.5–96.5)		Urinary irritative: 82.9 (71.3–94.4) Urinary incontinence: 91.5 (82.8–100) Bowel: 88.9 (82.4–95.5) Sexual: 35.7 (23–48.5) Hormonal: 86.3 (79.5–93)	

NR: Not reported

NSS: Not statistically significant

AS: Active surveillance

RP: Radical prostatectomy

NS: Nerve-sparing

NSRP: Nerve-sparing radical prostatectomy

EBRT: External beam radiotherapy

SBRT: Stereotactic body radiotherapy

IMRT: Intensity-modulated radiotherapy

BT: Brachytherapy

NHT: Neoadjuvant hormone therapy